David Risinger Analyst PerformanceSenior Managing Director & Senior Research Analyst at Leerink PartnersDavid Risinger is a stock analyst at Leerink Partners focused in the medical sector, covering 29 publicly traded companies. Over the past year, David Risinger has issued 27 stock ratings, including buy and hold recommendations. While full access to David Risinger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Risinger's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings134 Last 11 YearsBuy Recommendations46.21% 61 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution132RatingsDistribution of strong buy, buy, hold, and sell ratings by David Risinger.RatingPercentageCount Strong Buy0.0%0 ratings Buy46.2%61 ratings Hold48.5%64 ratings Sell5.3%7 ratingsOut of 132 total stock ratings issued by David Risinger at Leerink Partners, the majority (48.5%) have been Hold recommendations, followed by 46.2% Buy and 5.3% Sell.Best & Worst CallsBest Call000.0%JNJJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHCJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ58.6% of companies on NASDAQ17 companiesNYSE41.4% of companies on NYSE12 companiesDavid Risinger, an analyst at Leerink Partners, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical28 companies96.6%Manufacturing1 company3.4%David Risinger of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies44.8%LARGE CAP PHARMA5 companies17.2%MED - DRUGS3 companies10.3%MED - GENERIC DRG2 companies6.9%MED PRODUCTS2 companies6.9%PHARMACEUTICAL PREPARATIONS1 company3.4%BIOTECHNOLOGY1 company3.4%MED - OUTP/HM CRE1 company3.4%MEDICAL SERVICES1 company3.4% About David RisingerDavid Risinger, CFA is a Senior Managing Director and Senior Research Analyst at Leerink Partners covering Diversified Biopharmaceuticals. Prior to joining the Firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021. He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.Follow on LinkedIn David Risinger's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsJNJJohnson & Johnson5/13/2026Upgrade$224.44$265.00Outperform$0.0000.00% ROIKLRAKailera Therapeutics5/12/2026Initiated Coverage$22.93$36.00Outperform$0.0000.00% ROIORKAOruka Therapeutics4/30/2026Set Price Target$68.10$120.00$0.0000.00% ROIANABAnaptysBio4/28/2026Boost Price Target$66.59$85.00Outperform$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/24/2026Initiated Coverage$19.00$46.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals4/1/2026Downgrade$39.86$40.00Hold$0.0000.00% ROIORKAOruka Therapeutics3/16/2026Boost Price Target$41.52$86.00Outperform$0.0000.00% ROIAMGNAmgen3/5/2026Reiterated Rating$367.60$355.00Market Perform$0.0000.00% ROIXOMAXOMA Royalty2/24/2026Reiterated Rating$26.79Outperform$0.0000.00% ROIXOMAXOMA Royalty2/24/2026Boost Price Target$25.32$50.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. LLYEli Lilly and Company2/5/2026Boost Price Target$1,057.10$1,296.00Outperform$0.0000.00% ROIAMGNAmgen2/4/2026Boost Price Target$338.59$355.00Outperform$0.0000.00% ROIBMYBristol Myers Squibb1/13/2026Boost Price Target$56.40$60.00Outperform$0.0000.00% ROILLYEli Lilly and Company1/5/2026Set Price Target$1,079.83$1,234.00$0.0000.00% ROIVRTXVertex Pharmaceuticals12/29/2025Boost Price Target$462.90$525.00Outperform$0.0000.00% ROILLYEli Lilly and Company12/18/2025Reiterated Rating$1,062.10Outperform$0.0000.00% ROIROIVRoivant Sciences12/15/2025Boost Price Target$22.10$32.00Outperform$0.0000.00% ROIXOMAXOMA Royalty12/11/2025Lower Price Target$26.76$45.00Outperform$0.0000.00% ROIPCVXVaxcyte11/19/2025Set Price Target$49.53$77.00Outperform$0.0000.00% ROIROIVRoivant Sciences11/11/2025Reiterated Rating$21.17$29.00Outperform$0.0000.00% ROILLYEli Lilly and Company11/10/2025Upgrade$923.35$1,104.00Outperform$0.0000.00% ROIIMAImageneBio10/24/2025Initiated Coverage$7.39$30.00Outperform$0.0000.00% ROIHALOHalozyme Therapeutics10/14/2025Upgrade$67.72$70.00Market Perform$0.0000.00% ROIVRTXVertex Pharmaceuticals9/25/2025Upgrade$376.62$456.00Outperform$0.0000.00% ROIMTSRMetsera9/24/2025Reiterated Rating$52.95$57.00Market Perform$0.0000.00% ROIROIVRoivant Sciences9/18/2025Boost Price Target$15.28$22.00Outperform$0.0000.00% ROIMTSRMetsera9/9/2025Initiated Coverage$35.10$77.00Outperform$0.0000.00% ROIJNJJohnson & Johnson5/13/2025Downgrade$153.88$153.00Market Perform$000.0000.00% ROIVRTXVertex Pharmaceuticals5/6/2025Reiterated Rating$500.19$503.00Market Perform$000.0000.00% ROIREGNRegeneron Pharmaceuticals2/5/2025Upgrade$697.05$834.00Outperform$000.0000.00% ROIJNJJohnson & Johnson1/23/2025Lower Price Target$146.81$169.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageRoyal Bank Of CanadaJPMorgan Chase & Co.Berenberg BankWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
